NeuBase Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Other Prepaid Expenses and Current Assets

6 Months Ended

Jun. 30, 2023

3. Other Prepaid Expenses and Current Assets

The Company’s prepaid expenses and other current assets consisted of the following:


	As of June 30,		As of December 31,
	2023		2022
	Unaudited		Unaudited
Prepaid research and development expense	$	—	$	67,027
Accounts receivable		—		150,000
Other prepaid expenses and other current assets		399,414		174,628
Total	$	399,414	$	391,655